T-cell-engaging antibodies (TCEs) are synthetic molecules that redirect T cells to bind to the antigens on the surface of cancer cells to promote tumor elimination. In the case of multiple myeloma (MM), the approvals of anti-CD38 monoclonal antibodies (MAbs), chimeric antigen receptor T-cell therapies (CAR T) targeting B-cell maturation antigen (BCMA) or, more recently, bispecific TCEs represent great advances, but some patients still relapse after treatment.
Monopar Therapeutics Inc. has received human research ethics committee (HREC) clearance in Australia to commence a first-in-human phase I dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr in patients with advanced cancers.
Almirall S.A. has entered into an exclusive license agreement with Novo Nordisk A/S for global rights to develop and commercialize the IL-21-blocking monoclonal antibody NN-8828 in certain fields, including immune inflammatory dermatological diseases.
Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.
Researchers from Nextcure Inc. have reported the development and preclinical characterization of a novel agonist monoclonal antibody (MAb) against V-set and transmembrane domain containing 1 (VSTM-1).
CC-chemokine receptor 3 (CCR3) is a member of the G protein-coupled, seven-transmembrane receptor family expressed on mouse eosinophils, basophils, mast cells and mononuclear phagocytes, among others, that plays a role in allergic diseases such as allergic rhinitis.
Corbus Pharmaceuticals Holdings Inc. has obtained FDA clearance of its IND application for CRB-601, a TGF-β-blocking monoclonal antibody targeting the integrin αvβ8. Enrollment in a first-in-human phase I study will open in the first half of this year.
Sail Biomedicines Inc. has received two grants from the Bill & Melinda Gates Foundation to advance the company's Endless RNA (eRNA) platform to develop secreted monoclonal antibodies and vaccines for malaria.
Gigagen Inc., a subsidiary of Grifols SA, has received clearance from the FDA of its IND application to conduct a phase I trial of GIGA-564 for the treatment of solid tumors.
RSS
